What Redmontis saves you.
Three concrete benefits for a biotech executive and their CFO: time reclaimed, costs avoided, and credibility when the board and investors start asking questions.
Weeks of spreadsheet work given back to your core business.
Financial steering shouldn't cost you your days or hinge on a file only you understand.
The 3-hour turnaround and the 4-to-6-week manual rebuild come from feedback by CEO and CFO users.
18 000 €, set against the alternatives and the mistakes avoided.
Price isn't judged on its own, but next to what an executive pays today to steer their finances, and what a decision made too late ends up costing.
Sources: outsourced CFO, Pilot (Fractional CFO Cost Guide, 2026); horizontal FP&A tools, Vendr and Limelight (2026); impact of a single decision, 2 to 3 months of burn; market data, Panorama France HealthTech 2026.
Walk into the meeting with numbers that are ready and defensible.
- A single runway figure, same assumptions for the CEO, the CFO, the board and investors
- Scenarios compared so you can answer in the room, not afterward
- Use of Proceeds and reporting exported in one click, a stable format from one fundraise to the next
- Traceable assumptions, so numbers you can defend to a board or an auditor
A clear benefit for every decision-maker.
For the executive
You stay in control of your cash without spending your days on it, and stay focused on the science, execution and fundraising.
For finance
No more rebuilding Excel before every board: a single source, versioned scenarios, reporting ready to go.
For the board & investors
An instant read on the trajectory and the risks, in a consistent format from one meeting to the next.
Measure the gain on your own numbers.
A 30-minute demo is enough to see the time reclaimed and the clarity gained, on your clinical stage and your fundraising timeline.
Request a demo